别名：p53 (Acetyl K382); p53 (Acetyl Lys382); Acetyl-p53 (Lys382); Acetyl-p53(K382); Widespread p53; Wtp53; Antigen NY-CO-13; Cellular tumor antigen p53; Cys 51 Stop; HGNC11998; LFS1; p53; p53 Cellular Tumor Antigen; p53 Tumor Suppressor; Phosphoprotein p53; TP53; Transformation related protein 53; TRP53; Tumor protein p53; Tumour Protein p53; P53_HUMAN; TP53.
产品类型：乙酰化抗体
研究领域：肿瘤 细胞生物 神经生物学 信号转导 细胞凋亡
抗体来源：Rabbit
克隆类型：Polyclonal
交叉反应：Human (predicted: Dog)
产品应用：IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, Flow-Cyt=1μg/Test, ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理论分子量：43kDa
细胞定位：细胞核 细胞浆
性 状：Liquid
浓 度：1mg/ml
免 疫 原：KLH conjugated Synthesised acetylpeptide derived from human p53 around the acetylation site of K382: HK(Ac-K)LM
亚 型：IgG
纯化方法：affinity purified by Protein A
缓 冲 液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件：Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
注意事项：This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed：PubMed
产品介绍：This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013].
Function:Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
Subunit:Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with human cytomegalovirus/HHV-5 protein UL123.
Subcellular Location:Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2.
Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.
Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.
Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.
Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.
Isoform 9: Cytoplasm.
Tissue Specificity:Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
Post-translational modifications:Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1. Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage.
Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
Sumoylated by SUMO1.
DISEASE:Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni yndrome.
Similarity:Belongs to the p53 family.
SWISS:P04637
Gene ID:7157
Database links:
Entrez Gene: 7157 Human
Entrez Gene: 22059 Mouse
Entrez Gene: 24842 Rat
Omim: 191170 Human
SwissProt: P04637 Human
SwissProt: P02340 Mouse
SwissProt: P10361 Rat
Unigene: 654481 Human
Unigene: 222 Mouse
Unigene: 54443 Rat
wtp53广泛的研究发现P53肿瘤抑制基因对50%以上的人类癌症具有抑制突变的功能。P53蛋白水平在正常细胞中表达低，在DNA突变时或各种各样细胞遇难信号时反应增加。该基因突变或缺失是导致许多肿瘤发生的原因。
野生型P53(wt-p53)可诱导细胞凋亡，并通过细胞凋亡抑制肿瘤生长，而P53的突变或缺失则可抑制野生型P53的功能，使得缺陷细胞得以存活下来，从而导致肿瘤发生。
P53同时也是细胞凋亡的调控因子。此抗体可用于P53肿瘤抑制基因功能的研究。
产品类型：乙酰化抗体
研究领域：肿瘤 细胞生物 神经生物学 信号转导 细胞凋亡
抗体来源：Rabbit
克隆类型：Polyclonal
交叉反应：Human (predicted: Dog)
产品应用：IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, Flow-Cyt=1μg/Test, ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理论分子量：43kDa
细胞定位：细胞核 细胞浆
性 状：Liquid
浓 度：1mg/ml
免 疫 原：KLH conjugated Synthesised acetylpeptide derived from human p53 around the acetylation site of K382: HK(Ac-K)LM
亚 型：IgG
纯化方法：affinity purified by Protein A
缓 冲 液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件：Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
注意事项：This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed：PubMed
产品介绍：This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013].
Function:Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
Subunit:Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with human cytomegalovirus/HHV-5 protein UL123.
Subcellular Location:Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2.
Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.
Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.
Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.
Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.
Isoform 9: Cytoplasm.
Tissue Specificity:Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
Post-translational modifications:Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1. Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage.
Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
Sumoylated by SUMO1.
DISEASE:Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni yndrome.
Similarity:Belongs to the p53 family.
SWISS:P04637
Gene ID:7157
Database links:
Entrez Gene: 7157 Human
Entrez Gene: 22059 Mouse
Entrez Gene: 24842 Rat
Omim: 191170 Human
SwissProt: P04637 Human
SwissProt: P02340 Mouse
SwissProt: P10361 Rat
Unigene: 654481 Human
Unigene: 222 Mouse
Unigene: 54443 Rat
wtp53广泛的研究发现P53肿瘤抑制基因对50%以上的人类癌症具有抑制突变的功能。P53蛋白水平在正常细胞中表达低，在DNA突变时或各种各样细胞遇难信号时反应增加。该基因突变或缺失是导致许多肿瘤发生的原因。
野生型P53(wt-p53)可诱导细胞凋亡，并通过细胞凋亡抑制肿瘤生长，而P53的突变或缺失则可抑制野生型P53的功能，使得缺陷细胞得以存活下来，从而导致肿瘤发生。
P53同时也是细胞凋亡的调控因子。此抗体可用于P53肿瘤抑制基因功能的研究。
COA搜索：
免责申明：
本网站所提供的信息，只供参考之用。
本网站及其雇员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误对用户或任何其他人士负任何直接或间接的责任。
在法律允许的范围内，本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接或项目所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿（包括但不限于收益、预期利润的损失或失去的业务、未实现预期的节省）。
本网站所提供的信息，若在任何司法管辖地区供任何人士使用或分发给任何人士时会违反该司法管辖地区的法律或条例的规定或会导致本网站或其第三方代理人受限于该司法管辖地区内的任何监管规定时，则该等信息不宜在该司法管辖地区供该等任何人士使用或分发给该等任何人士。用户须自行保证不会受限于任何限制或禁止用户使用或分发本网站所提供信息的当地的规定。
本网站图片，文字之类版权申明，因为网站可以由注册用户自行上传图片或文字，本网站无法鉴别所上传图片或文字的知识版权，如果侵犯，请及时通知我们，本网站将在第一时间及时删除。
凡以任何方式登录本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。
通用销售条款
一． 买方对产品的使用：产品应当用于实验室研究目的，不可用作其他用途（包括但不限于：体外诊断、食品、药物、医疗器械、人用或兽用治疗、化妆品或其他商业用途）。购买方应明确清楚知道此声明，并严格遵守。如有任何因购买方隐瞒真实购买意图，由此引起的法律责任以及一切法律后果，由购买方承担。
二． 准确订货：下订单时，买方应预先仔细审阅产品的技术指标，确认无误。不详之处应立即查询。订单及产品一经发出，即视为买方认可有关产品的技术指标。
三． 质量责任：我司保证所供产品质量与随货COA所列标准相符。买方应以产品制造商的标准作为验收标准。鉴于化学品的特殊性，卖方对未使用之前的产品质量负责，对化学品的应用不负有任何直接与间接的责任。卖方提醒买方：在做实验之前，预先按照技术规范检验产品质量。在产品开始使用之后，买方对应用及其结果负有全部责任。若有质量异议，买方需在收到货物后10个工作日内书面通知卖方，过期无效。
四． 有限保证：在适用法律允许的最大限度内，卖方提供的产品均“按现状条件”提供给买方，卖方不作对产品和/或其使用的各种明示或默示的保证（包括但不限于对适销性、适合用于特殊用途及不侵权的所有明示或默示保证）或卖方产品会达到任何特定结果或不会被中断或不会有错误的保证。
五． 责任限制：在适用法律允许的最大限度内，卖方不对以任何方式由本合同、卖方产品或使用卖方产品引起的或与此有关的任何利润或收入损失或其他后果性损失、随附性损失、特殊损失、惩罚性损失或任何其他间接损失或损害承担责任。在适用法律允许的最大限度内，卖方的最高赔偿限额为买方就所涉及的卖方产品实际支付给卖方的价格。
六． 如卖方因不可抗拒力原因无法供货，卖方将及时通知买方，双方将视情况决定部分不履行、全部不履行或延期履行；如供货期限届满日为国内外重大节日或国家法定假日，则供货期限顺延；若因缺货导致延期交货或无法供货，卖方将及时告知买方，并不视为卖方违约。不可抗力：因火灾、洪水、风暴、爆炸、恐怖事件、战争、政府行为或任何其他卖方无法预见、无法避免和无法克服的事件造成延期交货或无法交货的，卖方不承担任何责任。
订购方式：
（1）直接注册www.ruichubio.com网站会员后直接在线订购支持支付宝、微信和公务卡支付；
（2）拨打021-59145618订购热线订购;
（3）登录www.ruichubio.com下载中心下载订购单发送至：order@ruichubio.com订购
注：在邮件确认合同或订购单情况下，可以货物和发票一起寄送，对公转账。
发票：
本公司出具增值税普通发票和增值税专用发票，适合您报销。发票面额为含税后的货物价格和运费，请您放心购买，我们会将运费开进发票里。请在拍下时在备注一栏里写上发票抬头。
支付：
开票账户：
公司名称 上海瑞楚生物科技有限公司
电话 021-60543596
纳税人识别号 91310116057685530X
开户银行全称 中国银行股份有限公司上海市长宁支行
帐号 454663168779
支付宝转账请支付到如下账户
帐 户 名 上海瑞楚生物科技有限公司
账 号 epay@ruichubio.com
为了方便高校科研单位公务卡结算，本网站开通了公务卡支付。可以在线下单选择支付宝付款，登录支付宝账号添加银行卡（输入公务卡号就可以）（公务卡一般就是信用卡,请按信用卡支付方式支付)。
运输：
（1）生物试剂需要冷冻运输，运输需要泡沫盒和一定量的冰袋（特殊商品需要干冰），运费金额会开进发票里。运费以显示为准
（2）常规试剂采用快递，运费以显示为准。
（3）大物件一般默认发德邦物流，运费需联系客服计算。
本网站所提供的信息，只供参考之用。
本网站及其雇员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误对用户或任何其他人士负任何直接或间接的责任。
在法律允许的范围内，本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接或项目所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿（包括但不限于收益、预期利润的损失或失去的业务、未实现预期的节省）。
本网站所提供的信息，若在任何司法管辖地区供任何人士使用或分发给任何人士时会违反该司法管辖地区的法律或条例的规定或会导致本网站或其第三方代理人受限于该司法管辖地区内的任何监管规定时，则该等信息不宜在该司法管辖地区供该等任何人士使用或分发给该等任何人士。用户须自行保证不会受限于任何限制或禁止用户使用或分发本网站所提供信息的当地的规定。
本网站图片，文字之类版权申明，因为网站可以由注册用户自行上传图片或文字，本网站无法鉴别所上传图片或文字的知识版权，如果侵犯，请及时通知我们，本网站将在第一时间及时删除。
凡以任何方式登录本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。
通用销售条款
一． 买方对产品的使用：产品应当用于实验室研究目的，不可用作其他用途（包括但不限于：体外诊断、食品、药物、医疗器械、人用或兽用治疗、化妆品或其他商业用途）。购买方应明确清楚知道此声明，并严格遵守。如有任何因购买方隐瞒真实购买意图，由此引起的法律责任以及一切法律后果，由购买方承担。
二． 准确订货：下订单时，买方应预先仔细审阅产品的技术指标，确认无误。不详之处应立即查询。订单及产品一经发出，即视为买方认可有关产品的技术指标。
三． 质量责任：我司保证所供产品质量与随货COA所列标准相符。买方应以产品制造商的标准作为验收标准。鉴于化学品的特殊性，卖方对未使用之前的产品质量负责，对化学品的应用不负有任何直接与间接的责任。卖方提醒买方：在做实验之前，预先按照技术规范检验产品质量。在产品开始使用之后，买方对应用及其结果负有全部责任。若有质量异议，买方需在收到货物后10个工作日内书面通知卖方，过期无效。
四． 有限保证：在适用法律允许的最大限度内，卖方提供的产品均“按现状条件”提供给买方，卖方不作对产品和/或其使用的各种明示或默示的保证（包括但不限于对适销性、适合用于特殊用途及不侵权的所有明示或默示保证）或卖方产品会达到任何特定结果或不会被中断或不会有错误的保证。
五． 责任限制：在适用法律允许的最大限度内，卖方不对以任何方式由本合同、卖方产品或使用卖方产品引起的或与此有关的任何利润或收入损失或其他后果性损失、随附性损失、特殊损失、惩罚性损失或任何其他间接损失或损害承担责任。在适用法律允许的最大限度内，卖方的最高赔偿限额为买方就所涉及的卖方产品实际支付给卖方的价格。
六． 如卖方因不可抗拒力原因无法供货，卖方将及时通知买方，双方将视情况决定部分不履行、全部不履行或延期履行；如供货期限届满日为国内外重大节日或国家法定假日，则供货期限顺延；若因缺货导致延期交货或无法供货，卖方将及时告知买方，并不视为卖方违约。不可抗力：因火灾、洪水、风暴、爆炸、恐怖事件、战争、政府行为或任何其他卖方无法预见、无法避免和无法克服的事件造成延期交货或无法交货的，卖方不承担任何责任。
订购方式：
（1）直接注册www.ruichubio.com网站会员后直接在线订购支持支付宝、微信和公务卡支付；
（2）拨打021-59145618订购热线订购;
（3）登录www.ruichubio.com下载中心下载订购单发送至：order@ruichubio.com订购
注：在邮件确认合同或订购单情况下，可以货物和发票一起寄送，对公转账。
发票：
本公司出具增值税普通发票和增值税专用发票，适合您报销。发票面额为含税后的货物价格和运费，请您放心购买，我们会将运费开进发票里。请在拍下时在备注一栏里写上发票抬头。
支付：
开票账户：
公司名称 上海瑞楚生物科技有限公司
电话 021-60543596
纳税人识别号 91310116057685530X
开户银行全称 中国银行股份有限公司上海市长宁支行
帐号 454663168779
帐 户 名 上海瑞楚生物科技有限公司
账 号 epay@ruichubio.com
为了方便高校科研单位公务卡结算，本网站开通了公务卡支付。可以在线下单选择支付宝付款，登录支付宝账号添加银行卡（输入公务卡号就可以）（公务卡一般就是信用卡,请按信用卡支付方式支付)。
运输：
（1）生物试剂需要冷冻运输，运输需要泡沫盒和一定量的冰袋（特殊商品需要干冰），运费金额会开进发票里。运费以显示为准
（2）常规试剂采用快递，运费以显示为准。
（3）大物件一般默认发德邦物流，运费需联系客服计算。
